详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Tirofiban After Successful MT Recanalization in AIS

122| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究单位： [1]Tongji Hospital [2]Wuhan Central Hospital [3]Wuhan University [4]Renmin Hospital of Wuhan University [5]Second Affiliated Hospital of Soochow University [6]The First Affiliated Hospital of Zhengzhou University [7]Wuhan Hospital of Traditional Chinese Medicine [8]The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture [9]Huangshi Central Hospital, China [10]The First Affiliated Hospital of Yangtze University [11]The Fifth Hospital of Wuhan [12]Wuhan Puren Hospital [13]Xiangyang No.1 People's Hospital [14]Xianning Central Hospital [15]Wuhan Hanyang Hospital [16]Wuhan Third Hospital [17]Yichang Central People's Hospital [18]Affiliated Hospital of Chengde Medical University [19]Beijing Tiantan Hospital [20]Nanyang Central Hospital [21]Jingzhou Central Hospital [22]Taihe Hospital [23]The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

关键词： mechanical thrombectomy acute ischemic stroke successful recanalization tirofiban

研究目的：

Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.